Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients

Pier Luigi Zinzani, Cinzia Pellegrini, Vittorio Stefoni, Enrico Derenzini, Letizia Gandolfi, Alessandro Broccoli, Lisa Argnani, Federica Quirini, Stefano Pileri, Michele Baccarani

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alphainterferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients. METHODS: The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n = 53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines. RESULTS: In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years). CONCLUSIONS: This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response.

Original languageEnglish
Pages (from-to)4788-4792
Number of pages5
Issue number20
Publication statusPublished - 2010


  • Alpha-interferon
  • Cladribine
  • Hairy cell leukemia
  • Pentostatin
  • Rituximab
  • Splenectomy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients'. Together they form a unique fingerprint.

Cite this